DE60335711D1 - Toluol-Solvat von Darifenacin - Google Patents

Toluol-Solvat von Darifenacin

Info

Publication number
DE60335711D1
DE60335711D1 DE60335711T DE60335711T DE60335711D1 DE 60335711 D1 DE60335711 D1 DE 60335711D1 DE 60335711 T DE60335711 T DE 60335711T DE 60335711 T DE60335711 T DE 60335711T DE 60335711 D1 DE60335711 D1 DE 60335711D1
Authority
DE
Germany
Prior art keywords
darifenacin
toluene solvate
solvate
toluene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335711T
Other languages
English (en)
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Garry O'oconnor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Original Assignee
Novartis International Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60335711(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd filed Critical Novartis International Pharmaceutical Ltd
Application granted granted Critical
Publication of DE60335711D1 publication Critical patent/DE60335711D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60335711T 2002-03-26 2003-03-17 Toluol-Solvat von Darifenacin Expired - Lifetime DE60335711D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
DE60335711D1 true DE60335711D1 (de) 2011-02-24

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335711T Expired - Lifetime DE60335711D1 (de) 2002-03-26 2003-03-17 Toluol-Solvat von Darifenacin

Country Status (23)

Country Link
US (3) US6930188B2 (de)
EP (2) EP1490357B1 (de)
JP (2) JP2005524678A (de)
KR (4) KR101026283B1 (de)
CN (1) CN100345840C (de)
AR (1) AR042608A1 (de)
AT (1) ATE495169T1 (de)
AU (1) AU2003209921A1 (de)
BR (2) BRPI0308706B8 (de)
CA (1) CA2480287C (de)
CY (2) CY1111200T1 (de)
DE (1) DE60335711D1 (de)
DK (2) DK1490357T3 (de)
ES (2) ES2358644T3 (de)
GB (1) GB0207104D0 (de)
HK (2) HK1080847A1 (de)
PA (1) PA8569701A1 (de)
PT (2) PT2336124E (de)
SI (2) SI1490357T1 (de)
SV (1) SV2003001515A (de)
TW (1) TW200306816A (de)
UY (1) UY27735A1 (de)
WO (1) WO2003080599A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
CA2626715A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for preparing darifenacin hydrobromide
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
BRPI0807615A8 (pt) * 2007-02-23 2017-12-05 Theravance Inc Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
CN101983187A (zh) 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (de) 2009-04-01 2010-10-06 Ragactives, S.L. Methode zur Herstellung von 1,3-difunktionalisierten Pyrrolidin-Derivaten
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2018007152A (es) * 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
KR102430610B1 (ko) * 2016-08-12 2022-08-08 바이엘 크롭사이언스 악티엔게젤샤프트 치환된 스티렌 유도체의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
CA2266070A1 (en) * 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
KR20120098888A (ko) 2012-09-05
GB0207104D0 (en) 2002-05-08
AU2003209921A1 (en) 2003-10-08
US20050245597A1 (en) 2005-11-03
US20030191176A1 (en) 2003-10-09
KR101212908B1 (ko) 2012-12-14
EP2336124B1 (de) 2012-08-29
PA8569701A1 (es) 2003-12-10
JP2010195828A (ja) 2010-09-09
ATE495169T1 (de) 2011-01-15
JP2005524678A (ja) 2005-08-18
CA2480287A1 (en) 2003-10-02
US7696357B2 (en) 2010-04-13
CY1111200T1 (el) 2015-06-11
KR20100101182A (ko) 2010-09-16
PT2336124E (pt) 2012-12-12
BR122018000397B8 (pt) 2021-07-27
CN1642945A (zh) 2005-07-20
EP1490357B1 (de) 2011-01-12
BRPI0308706B8 (pt) 2021-05-25
BR0308706A (pt) 2005-01-04
SI1490357T1 (sl) 2011-05-31
KR20040093477A (ko) 2004-11-05
BRPI0308706B1 (pt) 2018-07-10
WO2003080599A1 (en) 2003-10-02
US20080167367A1 (en) 2008-07-10
DK2336124T3 (da) 2012-12-17
EP1490357A1 (de) 2004-12-29
BR122018000397B1 (pt) 2019-07-02
PT1490357E (pt) 2011-03-01
ES2394067T3 (es) 2013-01-16
CN100345840C (zh) 2007-10-31
CY1113433T1 (el) 2016-06-22
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
CA2480287C (en) 2011-05-31
SI2336124T1 (sl) 2012-12-31
DK1490357T3 (da) 2011-04-04
HK1156626A1 (en) 2012-06-15
KR20110130539A (ko) 2011-12-05
US6930188B2 (en) 2005-08-16
AR042608A1 (es) 2005-06-29
ES2358644T3 (es) 2011-05-12
EP2336124A1 (de) 2011-06-22
SV2003001515A (es) 2003-12-15
KR101026283B1 (ko) 2011-03-31
HK1080847A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
ATE495169T1 (de) Toluol-solvat von darifenacin
FI113616B (fi) Instrumentti
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
NO20043696L (no) Gamma-sekretaseinhibitorer
DE60235192D1 (de) Abdeckung
DE60301072D1 (de) Handschuh
DE60321046D1 (de) Klettverschlüsse
DE60321717D1 (de) Schwungrad
DE50306533D1 (de) Deckel
FR2841960B1 (fr) Bague de traversee de cloison
NO20043664L (no) Ny fremgangsmate
DE60328306D1 (de) Drucktuch
DE50313181D1 (de) Alkyl-und/oder alkylenoligoglycosid-betainesterquats
FR2843451B1 (fr) Fronde du type lance-pierres
ITMI20021327A1 (it) Nuove ossialchilpiperazine
DE60331820D1 (de) Beseitigung von verstopfungen von rohrleitungen
FI20021294A0 (fi) Eristin
FI6126U1 (fi) Avoimen rakentamisen tehokas toteuttaminen
DE50300654D1 (de) Flachdichtung
DE50200691D1 (de) Spannungskomparator
UA6746S (uk) Кобза чотириструнна
NO20022407D0 (no) Sparkkoffert
FIU20020171U0 (fi) Puupalkki
SE0202929D0 (sv) Novel benzothiazepines and uses thereof
SE0202486L (sv) Uppfinningens svänghjul

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN